Press Room

ISySyCat21

Start
Tuesday, August 31, 2021 - 09:00
End
Friday, September 03, 2021 - 09:00
Location: Evora, Portugal
ISySyCat21 - Hovione gold sponsor catalysis

Hovione is present at the International Symposium on Synthesis and Catalysis 2021 (ISySyCat2021) taking place at the University of Evora in the historically recognized mediaeval city of Evora from August 31st to September 3rd 2021.

The conference will be a mixed event, in person to be hold in Evora, Portugal (with a limited number of participants) and on-line (webinar). 

The conference will focus on key topics in contemporary organic, organometallic, polymer synthesis and catalysis, which are of relevance to both academic and industrial chemists alike. This is reflected in the topics that will be discussed in the plenary lectures.

 

 

Hovione will present a topic at the plenary lectures with the following details:

 

Natural potential: biocatalyzed asymmetric synthesis of chiral amines

The presentation will address the screening and optimization of biocatalysts for the synthesis of chiral amines of interest in the manufacture of APIs.

Presenter: Ágnes Lakó
Date: 31st August
Time: 3:15 pm - 3:30 pm

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026